Tazemetostat

Tablet · trading as Tazverik

To Be Discontinued Active (discontinuing) — Day 48 FDA record updated 03/27/2026

High impact — Sole-source drug with no supply currently available from this manufacturer.

Editor of record: Branmoor Editorial · [email protected]

FDA shortage record

Substance

Tazemetostat

Brand name

Tazverik

Manufacturers / suppliers

Epizyme, Inc.
Epizyme, Inc. (An Ipsen Company)

2 known suppliers in current FDA data

Dosage form

Tablet

Presentation

Tazverik, Tablet, 200 mg (NDC 72607-100-00)

Route(s)

ORAL

Therapeutic category

Oncology

Package NDC

72607-100-00

Initially posted

03/27/2026

Days on shortage list

Discontinued

03/27/2026

Current FDA status

To Be Discontinued

Shortage entries (current dataset)

1 record for Tazemetostat

Why this shortage matters

Oncology drugs treat cancers including solid tumors, leukemia, and lymphoma. Shortages of chemotherapy agents can delay or interrupt regimens where dose timing and intensity directly affect treatment outcomes.

FDA therapeutic class: Oncology

Reason and context

Discontinuation of the manufacture of the drug product

Manufacturer contact

Per the FDA record, the manufacturer's contact for supply inquiries is (855)-463-5127.

If you're affected by this shortage

Talk to your prescribing clinician or pharmacist about therapeutic alternatives. Do not switch medications on your own.
Ask your pharmacy to check supply across multiple wholesalers and other branches.
Check current pharmacy pricing and availability via GoodRx (affiliate link).
Report a continuing supply problem to FDA via the FDA Drug Shortages contact form.

Sources

FDA Drug Shortages database, accessed via the openFDA Drug Shortages API.
FDA Structured Product Label (SPL set ID 7db07b5f-4e22-467c-9c0a-f830b08dbb1d).
FDA UNII identifier: 6P89T5M073.
See the Drug Shortage Tracker methodology for sourcing, update cadence, normalization rules, and limits.

Important

This page reproduces publicly available FDA shortage data for informational purposes only. It is not medical advice and does not establish a clinician-patient relationship. Shortage status changes frequently; verify directly with your pharmacist or the FDA Drug Shortages site before making any treatment decision.